the aid library

LIST OPTIONS

Filter

4015

WHO Sierra Leone Country Cooperation Strategy 2022–2025

World Health Organisation (WHO) (2023) C_WHO

The Country Cooperation Strategy is the World Health Organization’s corporate framework developed in response to a country’s needs and priorities. The 2022–2025 CCS is the fourth for WHO in Sierra Leone. It is a medium-term strategic document that defines a broad framework for WHO’s work, at... more

External Link

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

UN Children's Fund UNICEF (2023) CC

This report makes clear that there is a path to end AIDS. Taking that path will help ensure preparedness to address other pandemic challenges, and advance progress across the Sustainable Development Goals. The data and real-world examples in the report make it very clear what that path is. It is not... more

Download (190)

View PDF (188)

Global Strategic preparedness, readiness and response plan for Cholera
recommended

World Health Organisation (WHO) (2023) CC

Cholera is a major health risk in many parts of the world, affecting millions of people every year. Since mid-2021, the world has been facing an acute upsurge of the 7th cholera pandemic, which is characterized by the number, size and concurrence of multiple outbreaks, the spread to areas that had b... more

Download (165)

View PDF (165)

Voluntary non-remunerated blood donations to ensure blood safety in the WHO South-East Asia Region to support universal health coverage

World Health Organisation (WHO) (2023) C_WHO

Access to safe blood and blood products is recognized as one of the key requirements for delivery of modern health care in the journey towards health for all. The foundation of safe and sustainable blood supplies depends on the collection of blood from voluntary non-remunerated and low-risk donors. ... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (267)

View PDF (135)

WHO Emergency Response Framework - Internal WHO procedures - Second Edition

World Health Organization WHO (2024) C_WHO

The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore a... more

Download (173)

View PDF (286)

A Glimmer of Light in Venezuela’s Gloom - Latin America Report N°75 | 15 July 2019

International Crisis Group (2019) C1

Download (191)

View PDF (350)

COMPLEX HUMANITARIAN EMERGENCY IN VENEZUELA. Right to Water. October 2018

Aquaclara, et al. (2018) C1

Download (134)

View PDF (128)

Climate Risk Country Profile Paraguay

World Bank Group (2021) CC

Climate change is a major risk to good development outcomes, and the World Bank Group is committed to playing an important role in helping countries integrate climate action into their core development agendas. The World Bank Group is committed to supporting client countries to invest in and build a... more

Download (251)

View PDF (217)

Drugs and age - Drugs and associated issues among young people and older people

United Nations Office on Drugs and Crime (2018) C2

World Drug Report 2018 -4-

Download (126)

View PDF (153)

"I ripped the IV out and started running". Health care attacks in Yemen

Physicians for Human Rights; Mwatana for Human Rights (2020) C1

Indiscriminate attacks on health care have contributed to an epic humanitarian catastrophe in Yemen. A new report tracks these attacks in the hope of holding perpetrators on all sides accountable. It details how both Houthi forces—with their use of wide-area impact weapons—and the Saudi-Emir... more

External Link

Global Biodiversity Outlook 5

Convention on Biological Diversity (2020) C2

Global Biodiversity Outlook (GBO) is the flagship publication of the Convention on Biological Diversity (CBD). It is a periodic report that summarizes the latest data on the status and trends of biodiversity and draws conclusions relevant to the further implementation of the Convention. GBO-5 provi... more

Download (149)

View PDF (210)

Considerations for implementing and adjusting public health and social measures in the context of COVID-19
recommended

World Health Organization WHO (2021) C_WHO

interim guidance, 14 June 2021 This document is intended for national authorities and decision makers in countries that have introduced large scale public health and social measures. It offers guidance for adjusting public health and social measures, while managing the risk of a resurgence of cases... more

The path that ends AIDS: UNAIDS Global AIDS Update 2023 recommended

Global Strategic preparedness, readiness and response plan for Cholera recommended

Considerations for implementing and adjusting public health and social measures in the context of COVID-19 recommended

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

Global Strategic preparedness, readiness and response plan for Cholera
recommended

Considerations for implementing and adjusting public health and social measures in the context of COVID-19
recommended